BIOTA HOLDINGS ANNOUNCES ACQUISITION OF US-BASED NUMAX PHARMACEUTICALS
Question 1:
Why did Biota Holdings acquire NuMAX Pharmaceuticals?
Biota has for some time been looking for opportunities to build its portfolio of antiviral projects and to expand its activities in the US. In acquiring NuMAX, Biota achieves both these goals. NuMAX is an early stage startup company with novel technology for the rapid identification of new drug candidates in the nucleoside / nucleotide class. The technology developed by Dr P Dan Cook, an experienced pharmaceutical chemist, will be applied to viral targets such as hepatitis B and herpes as well as to other infective agents. A parallel project will involve finding agents that can stimulate or suppress the immune system, an area of wide applicability in infectious diseases.
Question 2:
confirmed aquisition
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)